Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 27;108(52):20982-7.
doi: 10.1073/pnas.1111202108. Epub 2011 Dec 8.

Protein conformational dynamics in the mechanism of HIV-1 protease catalysis

Vladimir Yu Torbeev  1 , H Raghuraman, Donald Hamelberg, Marco Tonelli, William M Westler, Eduardo Perozo, Stephen B H Kent
Affiliations

Protein conformational dynamics in the mechanism of HIV-1 protease catalysis

Vladimir Yu Torbeev et al. Proc Natl Acad Sci U S A. .

Abstract

We have used chemical protein synthesis and advanced physical methods to probe dynamics-function correlations for the HIV-1 protease, an enzyme that has received considerable attention as a target for the treatment of AIDS. Chemical synthesis was used to prepare a series of unique analogues of the HIV-1 protease in which the flexibility of the "flap" structures (residues 37-61 in each monomer of the homodimeric protein molecule) was systematically varied. These analogue enzymes were further studied by X-ray crystallography, NMR relaxation, and pulse-EPR methods, in conjunction with molecular dynamics simulations. We show that conformational isomerization in the flaps is correlated with structural reorganization of residues in the active site, and that it is preorganization of the active site that is a rate-limiting factor in catalysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Structural features of HIV-1 protease. (A) Homodimeric catalytically active form of HIV-1 protease (2 × 99 amino acids) complexed with the peptidomimetic reduced isostere-containing MVT-101 inhibitor. (B) The β-turn structures (residues 37–61) from each monomer, known as “flaps,” donate hydrogen bonds to the substrate (or inhibitor) through a structural water (water 301) molecule (in green). (C) Flaps with β-turn type I (Upper Left) and β-turn type II (Lower Right) conformations depicted separately for clarity. Residue Gly51 has D-amino acid conformation in the β-turn type I structure and L-amino acid conformation in the β-turn type II structure. (D) Flap X-ray structures in chemically synthesized [L-Ala51; D-Ala51′] covalent dimer HIV-1 protease molecule; 2Fo - Fc electron density contoured in blue at 1.5σ level for the 1.6-Å resolution crystal structure [Protein Data Bank (PDB) ID code 3FSM; see SI Appendix].
Fig. 2.
Fig. 2.
Dynamic properties of chemically synthesized Gly51 analogues of HIV-1 protease. (A) “Snapshots” of the conformational states (open, semiopen, and closed overlaid in B) of HIV-1 protease chemical analogues labeled with nitroxide-spin label, measured at 55 K using pulse-EPR spectroscopy. Populations of conformers are depicted for Gly51, L-Ala51, D-Ala51 and Aib51 homodimers in green, blue, red, and black, respectively. In the case of the D-Ala51 homodimer analogue, the semiopen conformer is overpopulated. (C) 15N-HSQC spectra overlaid for L-Ala51, D-Ala51, and Aib51 homodimers with the same color coding as in A. Peaks for the wild-type HIV-1 protease (in green) for corresponding residues were reconstructed from a previous study (21). Order parameters S2, obtained by model-free analysis of R1, R2 and 1H-15N NOE values, versus residue number are depicted as Inset. (D) CPMG 15N relaxation dispersion data for catalytic residue Asp25 in three HIV-1 protease symmetric homodimers obtained at two magnetic fields (600 and 900 MHz). Remarkably, the chemical exchange rates for the three analogue enzyme molecules are drastically different, and are correlated with the dynamic properties of the flaps and with the catalytic rates for proteolysis (Table 1; entries 5, 7, and 8).
Fig. 3.
Fig. 3.
X-ray structures of HIV-1 protease and its ester chemical analogues 9 and 10 complexed with substrate-based inhibitors. (A and B) In complexes of enzymes 9 and 10 with MVT-101 inhibitor, the electron density for structural water 301 molecule is significantly diffused—most strikingly in the enzyme 10 complex (see B), where we could not locate clear density for a water molecule at the flaps/inhibitor interface. (C and D) Interestingly, with the mechanistically based hydrated ketomethylene inhibitor KVS-1 (9), water 301 is well-populated in structures of enzymes 9 and 10. Moreover, in the complex of enzyme 10, there is second structural water molecule. [In all structures, side chains are deleted for clarity except the residues of interest. The 2Fo - Fcelectron density map was contoured at 1.0 σ level (in magenta) for selected flap residues and water molecules, and at a level of 3σ (in green) for residues Asp25 and Asp25′. Distances between distal oxygens of two catalytic Asp25 and Asp25′ and PDB codes are specified for each structure].
Fig. 4.
Fig. 4.
Active-site structures revealed by MD simulations, and a scheme for the mechanism of HIV-1 protease catalysis taking into account the dynamics of the flaps. (A) An asymmetric structure of catalytic Asp25 and Asp25′ and the nucleophilic water molecule dominated in the MD trajectory for the asymmetric [L-Ala51; D-Ala51′] chemical analogue of HIV-1 protease with the L-domain having a protonated Asp25 and the D-domain having a charged Asp25′ side chain. (B) Symmetric structure for catalytic residues and nucleophilic water was observed as the most populous state in the MD simulation for the symmetric [L-Ala51; L-Ala51′] and [D-Ala51; D-Ala51′] chemical analogues. (C) Scheme for the mechanism of HIV-1 protease catalysis. Asymmetric conformers are preorganized for catalysis. Conformational isomerizations are depicted by blue arrows, and electron rearrangements are depicted by red arrows. TS1 and TS2 are earlier and later transition states, respectively, and E.I is the enzyme complex with the tetrahedral intermediate.
Fig. 5.
Fig. 5.
“Activity–flexibility” relationship for a series of chemical analogues of HIV-1 protease. The “activity” axis contains relative values of kcat and kcat/Km for enzyme analogues 1–8 (see Table 1) normalized to those of the wild-type enzyme 1. The “flexibility” axis is built based on the assumption that the flap structure of the enzyme molecule containing Gly at position 51 is most flexible, followed by molecules containing L-Ala, D-Ala, and Aib (α-aminoisobutyric acid) replacing Gly. Most of the data follow a general trend where higher flexibility leads to higher activity. The exception is enzyme analogue 2 with one flap containing L-Ala51 and another D-Ala51′.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med. 2003;9:867–873. - PubMed
    1. Nicholson LK, et al. Flexibility and function in HIV-1 protease. Nat Struct Biol. 1995;2:274–280. - PubMed
    1. Ishima R, Louis JM. A diverse view of protein dynamics from NMR studies of HIV-1 protease flaps. Proteins. 2008;70:1408–1415. - PubMed
    1. Perryman AL, Lin J-H, McCammon JA. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004;12:1108–1123. - PMC - PubMed
    1. Hornak V, Simmerling C. Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov Today. 2007;12:132–138. - PMC - PubMed

Publication types

Substances

LinkOut - more resources